열 시험 (Lutetium-177을 이용한 HER2 항체 요법) (RAD202)
상 고형 종양 환자에서 인간 표피 성장 인자 수용체 2에 대한 루테 티움 -177 방사선 표지 된 단일 도메인 항체 177LU-RAD202의 안전성 및 내약성에 대한 상 0/1 연구
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a first-in-human, Phase 0/1, open-label study of 177Lu-RAD202 consisting of a Screening Period, a Treatment Period with 177Lu-RAD202 and a Safety and Long-Term Follow-Up Period to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
Screening Period: Screening period of up to 4 weeks Phase I (Treatment Period): 177Lu-RAD202 dose escalation
- Treatment Period with each cycle lasting 6 weeks. Extension of the planned dose intervals are possible following discussion and agreement between the Sponsor and Investigator.
- Participants may be treated with multiple cycles as long as they appear to derive clinical benefit as determined by the Investigator and provided adequate clinical safety and organ dosimetry data.
- DLT observation period for 177Lu-RAD202 is 6 weeks following first injection of 177Lu-RAD202.
- Should an alternative treatment schedule be explored, the DLT observation period for 177Lu-RAD202 at that dose level will be the proposed cycle duration.
Safety Follow-Up Period:
- An End of Treatment Visit performed within 7 days of the last dose of 177Lu-RAD202
- A Safety Follow-up Visit performed every 12 ± 2 weeks from the End of Treatment Visit
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 초기 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Dimitris Voliotis, MD
- 전화번호: +1 646 535 5017
- 이메일: dv@radiopharmtheranostics.com
연구 장소
-
-
New South Wales
-
Kingswood, New South Wales, 호주, 2747
- 모병
- Nepean Hospital
-
연락하다:
- Veronica Wong, MD
- 전화번호: +61 2 4734 2156
- 이메일: Veronica.Wong@health.nsw.gov.au
-
Macquarie Park, New South Wales, 호주, 2109
- 모병
- Macquarie University Hospital
-
연락하다:
- Dhanusha Sabanathan, MD
- 전화번호: +61 2 9812 3000
- 이메일: dhanusha.sabanathan@mqhealth.org.au
-
Wollongong, New South Wales, 호주, 2500
- 모병
- Wollongong Hospital
-
연락하다:
- Udit Nindra, MD
- 전화번호: +61 2 4222 5200
- 이메일: udit.nindra@health.nsw.gov.au
-
-
Victoria
-
Fitzroy, Victoria, 호주, 3065
- 모병
- St Vincents Hospital, Melbourne
-
연락하다:
- Melissa Moore, MD
- 전화번호: +61 3 9231 2211
- 이메일: melissa.moore@svha.org.au
-
-
Western Australia
-
Murdoch, Western Australia, 호주, 6150
- 모병
- GenesisCare Murdoch
-
연락하다:
- Aviral Singh, MD
- 전화번호: +61 8 9366 1542
- 이메일: Aviral.Singh@genesiscare.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Aged 18 years and older.
-
Written, voluntary, informed consent of the participants must be obtained in compliance with institutional, regional, and federal guidelines.
-
Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to curative-intent therapy, or metastatic, with documented disease progression during or after their most recent line of anti-cancer therapy. Participants must be refractory to or intolerant of standard of care therapy or have no standard of care therapy available that is likely to provide clinical benefit.
Participant HER2 positivity is determined by local testing and is defined as a score of 3+ on immunohistochemical analysis IHC), or, defined as a score of 2+ on IHC and positive results on in situ hybridisation (ISH). HER2-low is defined as a score of 1+ on IHC analysis or a score of 2+ on IHC analysis with ISH negative. If the participant tumor's HER2 status is unknown, it may be determined in a pre-screening step whereby the participant is asked to provide written informed consent to have their tumor tissue undergo IHC testing as determined by a validated test (tumor tissue may be obtained from archived samples or from a freshly obtained biopsy).
-
Must have at least 1 measurable target lesion according to RECIST version 1.1.
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
-
Participants must have a life expectancy of ≥4 months in the opinion of the Investigator.
-
Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. WOCBP are defined as those who are not surgically sterile or post-menopausal. Female participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
-
WOCBP must agree to use a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.
-
Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 90 days after the last dose of 177Lu-RAD202. All male participants must agree to not donate sperm during the study and at least 90 days after the last dose of 177Lu-RAD202, whichever occurs later. Acceptable methods of contraception are described in Section 12.3.3 of the Protocol.
-
Participants with previously treated brain metastases are eligible to participate if:
- They are neurologically and radiologically stable (no evidence of progression by imaging; same imaging modality [magnetic resonance imaging (MRI) or computed tomography (CT) scan] must be used for each assessment),
- Do not require corticosteroids to treat associated neurological symptoms, and
- Participants have no history of leptomeningeal disease or spinal cord compression.
- Participants with active brain metastases untreated with brain-directed therapy such as radiotherapy, are not eligible.
Exclusion Criteria:
-
Participants who have any other known, active malignancy, except for treated cervical intraepithelial neoplasia, or nonmelanoma skin cancer. Participants with a history of malignancies of low recurrence potential who have received curative-intent therapy may be approved on a case-by-case basis in discussion with the study Sponsor, if it is determined not to put the participant at an increased risk of adverse drug effects and/or interfere with the integrity of study outcome.
-
Participants who have any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures such as participants with severe claustrophobia who are unresponsive to oral anxiolytics, participants with low back pain who cannot lie comfortably on an imaging table, participants who are hyperactive or hyperkinetic such that they cannot tolerate lying still for multiple time-point imaging procedures, etc.
-
Residual toxicity Grade ≥ 2 from previously administered therapy (except for alopecia). Patients with Grade 2 or higher toxicity due to prior treatment may be allowed on a case-by-case basis in discussion with study Sponsor provided it is deemed not to put the participant at a higher risk of treatment-related toxicity or interfere with the integrity of study data, e.g., participants with endocrinopathy on stable replacement therapy
-
Inadequate organ functions as reflected in laboratory parameters:
- Creatinine clearance or Body Surface Area (BSA) adjusted Estimated glomerular filtration rate (eGFR) (calculated using any clinically validated formula, preferably Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), or measured) < 60 mL/min
- Platelet count of < 80 x 109/L
- Absolute neutrophil count (ANC) < 1.5 x 109/L
- Haemoglobin < 9 g/dL
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x upper limit of normal (ULN), or > 5 x ULN for participants with known liver metastases
- Total bilirubin > 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin ≤ 3 x ULN
- For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≥ 1.5 or prothrombin time (PT) ≥ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≥1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR < 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.
-
Significant cardiovascular disease including:
- Unstable angina and/or myocardial infarction within 6 months prior to screening
- New York Heart Association Class II or greater congestive heart failure
- Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)
- QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec for females and QTcF > 450 msec for males on screening electrocardiogram (ECG) or congenital long QT syndrome
- Uncontrolled hypertension
- Known LVEF < 50%. (LVEF may be performed either by echocardiogram or other appropriate imaging modalities such as nuclear cardiac imaging (MUGA) or MRI).
-
History of uncontrolled allergic reactions and/or have hypersensitivity to anti-HER2 monoclonal antibodies, kanamycin A or aminoglycoside therapies, or other excipients that may induce hypersensitivity
-
Pregnant or lactating women
-
Participants who are receiving any other investigational agents
-
Received anti-cancer therapy, including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy or investigational device, within 28 days (or 5 half-lives for biologic/non-cytotoxic agents, whichever is shorter), prior to the first dose of 177Lu-RAD202.
-
Has had or is scheduled to have major surgery ≤ 28 days prior to the first dose of 177Lu-RAD202. Surgical procedures not considered to put participants at higher risk of AEs and/or interfere with the integrity of study outcome may be allowed on a case-by-case basis in discussion with the Sponsor.
-
Positive status for human immunodeficiency virus (HIV).
-
Active or chronic hepatitis B or C. Chronic hepatitis B or hepatitis C with undetectable viral loads on stable suppression therapy may be allowed on a case-by-case basis in discussion with study Sponsor.
-
Any medical condition which, in the opinion of the Investigator, places the participant at an unacceptably high risk for toxicities.
-
Any uncontrolled intercurrent illness or clinically significant uncontrolled condition(s), including but not limited to active bacterial, fungal, or viral infections requiring systemic therapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 177Lu-RAD202
Single-arm, open-label study of 177Lu-RAD202 |
177Lu-RAD202 administered at treatment doses |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and tolerability of 177Lu-RAD202
기간: 6 weeks
|
The properties, incidence, nature and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
6 weeks
|
|
Recommended dose(s) of 177Lu-RAD202 for future exploration
기간: 6 weeks
|
Incidence of dose-limiting toxicities (DLTs) during the first 6 weeks following 177Lu-RAD202 injection cycle of treatment |
6 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Preliminary antitumor activity of 177Lu-RAD202
기간: Up to 30 weeks
|
Objective response rates (ORR) as assessed by RECIST v1.1 |
Up to 30 weeks
|
|
Time Activity Curves (TACs)
기간: 72 hours
|
Percent of the injected activity vs time for selected organs and tumors |
72 hours
|
|
Radiation dosimetry of 177Lu-RAD202
기간: 72 hours
|
Absorbed radiation doses of 177Lu-RAD202tr in critical organs (e.g., kidneys, bone marrow) |
72 hours
|
|
Pharmacokinetics of 177Lu-RAD202
기간: 72 hours
|
Half-life of 177Lu-RAD202 in blood |
72 hours
|
|
Biokinetics of 177Lu-RAD202
기간: 72 hours
|
Time-integrated activity coefficients of 177Lu-RAD202 in organs and tumor lesions |
72 hours
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To explore the use of SPECT/CT as a measure of preliminary anti-tumor activity of 177Lu-RAD202
기간: Up to 30 weeks
|
Longitudinal assessments of quantitative tumor uptake of 177Lu-RAD202 using SPECT/CT |
Up to 30 weeks
|
|
To study the effect of amino acid infusion on 177Lu-RAD202 radiation absorption
기간: Up to 30 weeks
|
Absorbed radiation doses of 177Lu-RAD202 in critical organs (e.g. kidneys, bone marrow) |
Up to 30 weeks
|
|
Level of agreement between 177Lu-RAD202 and standard of care imaging
기간: Up to 30 weeks
|
Standard of care imaging may include but is not limited to 18F-FDG-PET, CT-scan and/or 99mTc-MDP-bone |
Up to 30 weeks
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- RAD202.2022.0002
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .